Rules-Based Medicine Withdraws IPO
November 12, 2010
Rules-Based Medicine Withdraws IPO
Citing "market conditions," the company, which last month released three new biomarker panels and plans to release a fourth in the next several weeks, pulled the initial public offering it filed for last December.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Myriad to Enter Proteomics Market with $80M Purchase of Rules-Based Medicine
April 29, 2011 / ProteoMonitor - TARC Team Uses RBM's DiscoveryMAP Platform to Develop Alzheimer's Protein-Biomarker Test
September 17, 2010 / ProteoMonitor - CPRIT Awards RBM $3M to Expand OncologyMAP Biomarker Panel; Launch Targeted for Fall
July 16, 2010 / ProteoMonitor - Myriad Highlights RBM Pharma Work, Reports $2M in Q4 Revenues from Companion Diagnostics
August 12, 2011 / ProteoMonitor - New Products
April 1, 2011 / ProteoMonitor